Elucidating the phase 1 trial experience among study participants following completion of the INTERCEPT-AD study of sabirnetug (ACU193) for early Alzheimer&#39;s disease: a qualitative interview study.

sabirnetug IV (ACU193 IV) - Acumen Pharma

http://www.ncbi.nlm.nih.gov/pubmed/41872889

Carrie Presnall; Diana Kerwin; Elizabeth Merikle; Eric Siemers; Robyn Moxon; Stephanie Cline; Todd Feaster

Mar 25, 2026